IRCT201110203930N13
Completed
Phase 2
Randomized placebo controlled clinical trial of the effect of hydroxyzine on bruxism in children and adolescents
Vice chancellor for research, Shiraz University of Medical Sciences0 sites30 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Bruxism.
- Sponsor
- Vice chancellor for research, Shiraz University of Medical Sciences
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Children with age range of 3 to 17 years from both gender with bruxism.
- •Exclusion criteria: Concurrent behavior therapy, psychoanalysis, or relaxation therapy for bruxism; taking benzodiazepines.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Efficacy of Gabapentin on flushing in menopausal womeIRCT201103011107N4Jundishapour Medical University60
Recruiting
Phase 1
Randomised, placebo-controlled clinical trial on the efficacy of Roleca® juniper 100 mg for dyspeptic digestive complaints such as cramps in the gastrointestinal tract, flatulence and bloating.Treatment of dyspeptic digestive complaints (cramps in the gastrointestinal tract, flatulence, bloating).Therapeutic area: Diseases [C] - Digestive System Diseases [C06]CTIS2023-504750-35-01CGBS GbR100
Completed
Not Applicable
Randomized, placebo-controlled clinical trial on the efficacy of a mouthrinse containing 0.1% benzalkoniumchloride on the reduction of intraoral viral load and infectivity in SARS-CoV-2 positive subjects (COVID-19)U07.1COVID-19, virus identifiedDRKS00024454Poliklinik für Zahnerhaltung und ParodontologieUniversitätsklinikum Regensburg24
Not yet recruiting
Phase 1
Randomized, Placebo-Controlled Clinical Trial of Transdermal dihydrotestosterone Gel to Improve In Vitro Fertilization Outcomes In Women With Poor Ovarian ResponseACTRN12615001115527Prof.David Handelsman242
Completed
Not Applicable
Imiquimod Plus Antimony Immunochemotherapy for Cutaneous LeishmaniasisPER-065-05DRUGS FOR NEGLECTED DISEASE INITIATIVE,